scholarly journals Effects of hormone therapy on health related quality of life in postmenopausal women with CAD differed according to presence of menopausal symptoms

2002 ◽  
Vol 5 (3) ◽  
pp. 83-83
Author(s):  
C. R Kessenich
Keyword(s):  
Quality Of Life ◽  
Hormone Therapy ◽  
Postmenopausal Women ◽  
Menopausal Symptoms ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

scholarly journals The impact of lumbar scoliosis on pain, function and health-related quality of life in postmenopausal women

2011 ◽  
Vol 20 (12) ◽  
pp. 2223-2227 ◽  
Author(s):  
Julio Urrutia ◽  
Julio Espinosa ◽  
Claudio Diaz-Ledezma ◽  
Carlos Cabello
Keyword(s):  
Quality Of Life ◽  
Postmenopausal Women ◽  
Health Related Quality ◽  
Lumbar Scoliosis ◽  
Related Quality ◽  
Health Related ◽  
The Impact

scholarly journals Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptor–Positive Breast Cancer (E-3193, INT-0142): A Trial of the Eastern Cooperative Oncology Group

2014 ◽  
Vol 32 (35) ◽  
pp. 3948-3958 ◽  
Author(s):  
Amye J. Tevaarwerk ◽  
Molin Wang ◽  
Fengmin Zhao ◽  
John H. Fetting ◽  
David Cella ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Premenopausal Women ◽  
Menopausal Symptoms ◽  
Phase Iii ◽  
Health Related Quality ◽  
Patient Reported ◽  
Related Quality ◽  
Health Related

Purpose The effects of ovarian function suppression (OFS) on survival and patient-reported outcomes were evaluated in a phase III trial in which premenopausal women were randomly assigned to tamoxifen with or without OFS. Patients and Methods Premenopausal women with axillary node-negative, hormone receptor–positive breast cancer tumors measuring ≤ 3 cm were randomly assigned to tamoxifen alone versus tamoxifen plus OFS; adjuvant chemotherapy was not permitted. Primary end points were disease-free survival (DFS) and overall survival (OS). Secondary end points included toxicity and patient-reported outcomes. Patient-reported outcome data included health-related quality of life, menopausal symptoms, and sexual function. These were evaluated at baseline, 6 months, 12 months, and then annually for up to 5 years after registration. Results In all, 345 premenopausal women were enrolled: 171 on tamoxifen alone and 174 on tamoxifen plus OFS. With a median follow-up of 9.9 years, there was no significant difference between arms for DFS (5-year rate: 87.9% v 89.7%; log-rank P = .62) or OS (5-year rate: 95.2% v 97.6%; log-rank P = .67). Grade 3 or higher toxicity was more common in the tamoxifen plus OFS arm (22.4% v 12.3%; P = .004). Patients treated with tamoxifen plus OFS had more menopausal symptoms, lower sexual activity, and inferior health-related quality of life at 3-year follow-up (P < .01 for all). Differences diminished with further follow-up. Conclusion When added to tamoxifen, OFS results in more menopausal symptoms and sexual dysfunction, which contributes to inferior self-reported health-related quality of life. Because of early closure, this study is underpowered for drawing conclusions about the impact on survival when adding OFS to tamoxifen.

scholarly journals Health-related quality of life and resilience in peri- and postmenopausal women during Covid-19 confinement

Maturitas ◽  
2021 ◽  
Vol 144 ◽  
pp. 4-10
Author(s):  
Pluvio J. Coronado ◽  
Maria Fasero ◽  
Borja Otero ◽  
Sonia Sanchez ◽  
Esther de la Viuda ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Postmenopausal Women ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related
Sign in / Sign up

Export Citation Format

Share Document